BiondVax Pharmaceuticals Ltd
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases.
Its previous vaccine candidate was first developed in the Weizmann Institute of Science laboratory of Professor Ruth Arnon and licensed by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, to BiondVax for further development. BiondVax executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of the vaccine candidate and built a state-of-the-art GMP biologics manufacturing facility in Jerusalem.
BiondVax is currently developing a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline in collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT) and the University Medical Center Göttingen (UMG) addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.
NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production.
BiondVax’s Chief Science Officer, Dr. Tamar Ben-Yedidia, completed her PhD at the Weizmann in Prof. Arnon’s lab, and Prof. Arnon continues to serve as the head of BiondVax’s Scientific Advisory Board (SAB). The company is traded on the Nasdaq under the ticker BVXV.
For additional information, please visit www.biondvax.com.